Priority Voucher Awarded to Bavarian Nordic
Federal Register notice: FDA has announced that it has issued a material threat medical countermeasure priority review voucher to Bavarian Nordic for recently approved Jynneos (smallpox and monkeypox vaccine, live, non-replicating). The agency determined that the product met criteria for the priority review voucher because it is intended to prevent smallpox infection. To view the notice, click here.